Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 4 | 2024 | 259 | 1.460 |
Why?
|
| Biomarkers, Tumor | 8 | 2025 | 512 | 1.240 |
Why?
|
| Head and Neck Neoplasms | 5 | 2023 | 167 | 1.070 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 410 | 0.830 |
Why?
|
| Epidermal Growth Factor | 2 | 2020 | 47 | 0.750 |
Why?
|
| Lung Neoplasms | 4 | 2025 | 695 | 0.730 |
Why?
|
| Chemoradiotherapy | 2 | 2017 | 77 | 0.650 |
Why?
|
| Melanoma | 4 | 2025 | 331 | 0.550 |
Why?
|
| Saliva | 1 | 2017 | 100 | 0.530 |
Why?
|
| Mutation | 3 | 2024 | 2629 | 0.510 |
Why?
|
| Circulating Tumor DNA | 3 | 2020 | 10 | 0.500 |
Why?
|
| Lipids | 1 | 2017 | 319 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2025 | 497 | 0.440 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2025 | 727 | 0.410 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2024 | 10 | 0.400 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2025 | 534 | 0.390 |
Why?
|
| MicroRNAs | 4 | 2024 | 697 | 0.370 |
Why?
|
| Trisomy | 1 | 2012 | 21 | 0.360 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 54 | 0.360 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 1211 | 0.340 |
Why?
|
| Cisplatin | 3 | 2022 | 146 | 0.320 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 34 | 0.320 |
Why?
|
| Gene Expression Profiling | 5 | 2025 | 783 | 0.320 |
Why?
|
| Brazil | 4 | 2025 | 100 | 0.300 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 1494 | 0.300 |
Why?
|
| Paclitaxel | 2 | 2019 | 103 | 0.280 |
Why?
|
| Telomerase | 2 | 2024 | 29 | 0.250 |
Why?
|
| Transcriptome | 3 | 2025 | 396 | 0.250 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 63 | 0.250 |
Why?
|
| Humans | 27 | 2025 | 64238 | 0.250 |
Why?
|
| ErbB Receptors | 3 | 2025 | 120 | 0.240 |
Why?
|
| Phosphatidylethanolamine Binding Protein | 1 | 2025 | 3 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 666 | 0.230 |
Why?
|
| CD24 Antigen | 1 | 2025 | 18 | 0.230 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 129 | 0.220 |
Why?
|
| Genotype | 3 | 2025 | 668 | 0.210 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2023 | 4 | 0.200 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2023 | 6 | 0.200 |
Why?
|
| Carcinoma, Papillary | 1 | 2023 | 37 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 189 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2025 | 265 | 0.190 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 75 | 0.190 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 276 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2023 | 115 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2024 | 309 | 0.180 |
Why?
|
| Middle Aged | 11 | 2025 | 17898 | 0.180 |
Why?
|
| Female | 15 | 2025 | 33350 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 518 | 0.170 |
Why?
|
| Male | 13 | 2025 | 30294 | 0.170 |
Why?
|
| Prognosis | 5 | 2025 | 1769 | 0.170 |
Why?
|
| Alleles | 2 | 2019 | 448 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1130 | 0.160 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 24 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 174 | 0.160 |
Why?
|
| Sentinel Lymph Node | 1 | 2020 | 13 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 349 | 0.160 |
Why?
|
| Pharmacogenomic Variants | 1 | 2019 | 3 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 27 | 0.160 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 44 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 207 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 116 | 0.150 |
Why?
|
| Melanins | 1 | 2019 | 25 | 0.150 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 59 | 0.150 |
Why?
|
| Genetics, Population | 1 | 2019 | 44 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2019 | 123 | 0.150 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 86 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 457 | 0.130 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2017 | 2 | 0.130 |
Why?
|
| Aged | 6 | 2025 | 14648 | 0.130 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 16 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 1 | 2017 | 51 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 421 | 0.130 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2016 | 12 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2020 | 416 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 685 | 0.120 |
Why?
|
| Adult | 6 | 2025 | 17116 | 0.120 |
Why?
|
| Risk Factors | 3 | 2025 | 5339 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1551 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5691 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1621 | 0.100 |
Why?
|
| Mice | 2 | 2025 | 11003 | 0.100 |
Why?
|
| Infant | 2 | 2024 | 1664 | 0.100 |
Why?
|
| Testicular Neoplasms | 2 | 2024 | 35 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2025 | 91 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2025 | 201 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5520 | 0.090 |
Why?
|
| Disorders of Sex Development | 1 | 2012 | 11 | 0.090 |
Why?
|
| Microcephaly | 1 | 2012 | 14 | 0.090 |
Why?
|
| Karyotype | 1 | 2012 | 18 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2012 | 24 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 358 | 0.090 |
Why?
|
| Cell Movement | 2 | 2025 | 466 | 0.090 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 104 | 0.080 |
Why?
|
| Self Report | 2 | 2023 | 388 | 0.080 |
Why?
|
| Disease Progression | 3 | 2020 | 1176 | 0.080 |
Why?
|
| Animals | 2 | 2025 | 20961 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 249 | 0.070 |
Why?
|
| Phenotype | 1 | 2012 | 1222 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 6304 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2019 | 759 | 0.060 |
Why?
|
| Fibronectins | 1 | 2025 | 43 | 0.060 |
Why?
|
| Mice, Nude | 1 | 2025 | 281 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 24 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 58 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 93 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 361 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 59 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 22 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 107 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 162 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 174 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 125 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2025 | 1001 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 210 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.040 |
Why?
|
| Tryptophan | 1 | 2020 | 56 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2020 | 49 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2020 | 60 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 51 | 0.040 |
Why?
|
| Lymphoscintigraphy | 1 | 2020 | 6 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2020 | 10 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2020 | 39 | 0.040 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 64 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 41 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2020 | 35 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2020 | 53 | 0.040 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 68 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6726 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 165 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 43 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2019 | 16 | 0.040 |
Why?
|
| Centrifugation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 229 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2025 | 2604 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2024 | 2018 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 529 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 294 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 575 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 357 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 851 | 0.030 |
Why?
|
| Mouth | 1 | 2016 | 34 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 412 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2017 | 124 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 423 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 735 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2020 | 909 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 930 | 0.030 |
Why?
|
| Child | 1 | 2024 | 4583 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 487 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 901 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1102 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 3315 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 1681 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3724 | 0.020 |
Why?
|